摘要
目的:评估胃癌以及胃癌肝转移介入治疗与单纯外科手术切除治疗间的疗效差别。方法:通过对254例患者的随访,获得包括生存率、预后情况等数据,运用生存分析法比较了不同治疗方案间的治疗效果。结果:单纯介入治疗组平均生存时间为26.4个月,中位生存期(MST)为21.1个月,1年生存率为62.1%,3年生存率为34.5%,5年生存率为3.4%。直接外科手术组平均生存时间为25.9个月,中位生存期为20.7个月,1年生存率为60%,3年生存率为31.1%,5年生存率为4.4%。放弃治疗的病例平均生存时间仅为6.7个月,中位生存期为4.3个月。先介入后手术组平均生存时间为34.6个月,中位生存期为23.4个月,1年生存率为65.8%,3年生存率为36.8%,5年生存率为7.9%。介入治疗后再行外科手术患者的生存率明显高于单独接受外科手术切除的患者,差异有统计学意义(P<0.05)。结论:介入治疗或通过介入治疗后再行外科手术对于晚期胃癌有较好的治疗效果。
Objective： To evaluate the effectiveness of Transcatheter Arterial Infusion （TAI）, TAI followed by surgery and direct surgery treatment （subtotal or total gastrictomy） in gastric cancer. Methods： Clinical data were collected from 254 patients with different treatments. The collected data with survival analysis model were fiarther analyzed. Results： In the group with TAI treatment only, the average survival time is 26.4 months, the Median Survival Time （MST） is 21.1 months, 1 year survival is 62.1%, 3 year survival time is 34.5%, and 5 year survival rate is 3.4%. In the group with surgery treatment only, the average survival rate is 25.9 months, the MST value is 20.7 months, 60% patients survived after 1 year, after 3 years, there were still 31.1% patients surviving, and only 4.4% patients survived after 5 years. A small group of patients refused to receive any treatment after primary treatment, the average survival time is 6.7 months, and the MST is 4.3 months. A group of 38 patients decided to receive a TAI treatment first and then with subtotal or total gastrictomy, this group got a 34.6 months average survival time, the MST is 23.4, 65.8% patients survived after 1 year, the 3 year and 5 year survival rate is 36.8% and 7.9%. The survival rate of Patients treated with TAI followed by surgery is significantly higher than common surgery treatment （P〈0.05）. Conclusions： TAI treatment is recognized as an effective method for stage Ⅲ or Ⅳ gastric cancer.
出处
《交通医学》
2012年第3期217-220,共4页
Medical Journal of Communications
关键词
胃癌
胃癌肝转移
介入治疗
手术治疗
存活率
gastric cancer
liver metastasis
transcatheter arterial infusion
surgery treatment
survival rate
